As more companies enter the drug development segment of the psychedelics space, we’re beginning to see overlap among research pipelines. This week, PharmaDrug announced that it has filed for FDA Orphan Drug Designation for DMT in stroke. Just last week, Algernon Pharmaceuticals announced their clinical research program for the treatment of stroke with DMT, and related provisional patent filings.


Previous articlePsychedelic Business News Spotlight: February 12, 2021
Next articleWhy The Future of The Psychedelic Industry Could Be In The Hands of Retail Investors